Novartis India Ltd - NOVARTIS INDIA Share Price

Sector: Pharmaceuticals | ISIN: INE234A01025
₹ 672.25 (-2.48%) icon25 Oct, 2023, 3:57:48 PM

Novartis India Ltd KEY RATIOS

sector: Trading

  • CMP

    as on 10/25/2023 3:57:48 PM

    ₹ 672.25 -17.10 -2.48
  • Open
  • ₹ 691.05
  • Prev. Close
  • ₹ 689.35
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 698.2
  • Day's Low
  • ₹ 668.35
  • 52 Week's High
  • ₹ 909
  • 52 Week's Low
  • ₹ 668.35
  • Book Value
  • ₹ 348.65
  • Face Value
  • ₹ 5
  • Mkt Cap (₹ Cr.)
  • 1,659.84
  • P/E
  • 31.42
  • EPS
  • 34.5
  • Divi. Yield
  • 2.31

Novartis India Ltd Corporate Actions

27 Mar , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

08 May , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

17 Feb , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

27 Dec , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

27 Dec , 2023

12:00 AM

30 Sep , 2023

12:00 AM

30 Sep , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

10 May , 2023

12:00 AM

AGM

Announcement date: 10 May , 2023

View Details

30 Jun , 2023

12:00 AM

30 Jun , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

10 May , 2023

12:00 AM

Dividend

Dividend amount: 10
Announcement date: 10 May , 2023

View Details

10 May , 2023

12:00 AM

Dividend

Dividend amount: 37.5
Announcement date: 10 May , 2023

View Details

10 May , 2023

12:00 AM

BookCloser

View Details

No Record Found


Novartis India Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Novartis India Ltd SHAREHOLDING SNAPSHOT
28 May , 2024 | 01:02 AM

PROMOTER - TOTAL70.68%

Indian: 0.00%

Foreign: 70.6769%

NON-PROMOTER - TOTAL 29.32%

Institutions: 0.72%

Non-Institutions: 28.60%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Novartis India Ltd FINANCIALS

View Profit & Loss Graph

Novartis India Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Novartis India Ltd

  • C Snook
  • Chairman (Non-Executive)
  • Jai Hiremath
  • Independent Director
  • Sandra Martryes
  • Independent Director
  • Sanjay Murdeshwar
  • Vice Chairman & M.D.
  • SANKER PARAMESWARAN
  • Independent Director
  • Shilpa Joshi
  • Whole Time Director & CFO
  • Chandni Maru
  • Company Sec. & Compli. Officer

Summary

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the worlds second largest pharmaceutical company was incorporated on 13 December 1947. The Company is focused on manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates in four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz. The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886. In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years. In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd. joined to form Novartis. In the year 1998, the company had set-up the Novartis Institute for Functional Genomics. During the year 2000, Novartis acquired the products Famvir and Vectavir/Denavir from SmithKline Beecham also in the same year, the company started to provide treatment to leprosy patients worldwide through World Health Organisation (WHO). Also in 2000, NIL had started JEET (Joint Effort to Eradicate Tuberculosis) with the aim of increasing awareness among TB patents and to involve doctors more actively in the fight against disease. After a year, Novartis Respiratory Research Centre, the largest of its kind in... Read More


Reports by Novartis India Ltd


Reports by Novartis India Ltd

Company FAQ

No Record Found